Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Neurology · C9ORF72-Associated Huntington Disease-Like Syndrome

Long-Term Monitoring and Future Directions

At a Glance

Long-term C9ORF72 monitoring should assess movement, thinking and behavior, speech and swallowing, and breathing—not just movement symptoms. FVC, SNIP, and research biomarkers can inform care, but no single test predicts an individual’s course or treatment response.

Living with the C9ORF72 expansion requires a shift in how you and your doctors think about “follow-up.” Because this condition can evolve across movement, thinking, and breathing, long-term care is about more than just monitoring your current symptoms—it is about longitudinal vigilance [1].

Even if you started with Huntington’s-like movements, your care team must remain “multilingual,” checking in on your cognitive health and your motor neurons at every visit [1][2].

The “Watchlist”: Objective Monitoring

Your doctors will use several objective tests to track the disease over time. This data helps them intervene early—for example, by starting a breathing aid before you feel short of breath [3].

  • Respiratory Strength: Standard lung tests like FVC (Forced Vital Capacity) are important, but for C9ORF72, doctors may also use SNIP (Sniff Nasal Inspiratory Pressure) [3][4]. This test measures the strength of your diaphragm, though it is effort-dependent and not uniformly more accurate than FVC. Assessment may also include supine FVC, cough strength, and nocturnal testing [3].
  • Bulbar and Swallowing Health: Monitoring for dysarthria (slurred speech) or dysphagia (difficulty swallowing) is critical [5]. Regular weight checks help ensure you are getting enough nutrition; formal swallowing studies are scheduled when indicated by symptoms rather than required for every patient [6][7].
  • Cognition and Behavior: Using specialized neuropsychological tests, your team can track changes in executive function or social behavior [2][8]. Note that the ECAS (Edinburgh Cognitive and Behavioural ALS Screen) was developed for ALS, so a tailored evaluation is often needed for the behavioral and movement issues in this phenotype.

Measuring Disease “Activity”: Biomarkers

Researchers are working on fluid biomarkers to understand disease activity [9]. While mostly used in research settings today, they have important clinical limitations [10].

  • Neurofilament Light Chain (NfL): This is a non-specific protein that leaks into the blood or spinal fluid when nerve cells are damaged [11]. While rising levels are associated with symptomatic disease in groups of patients, it is affected by age and other factors. A rising value alone cannot definitively diagnose onset, predict your specific phenotype, or determine treatment [12][13].
  • Poly(GP): These are dipeptide-repeat proteins (DPRs) produced by the C9ORF72 expansion [14]. In clinical trials, they are used as a pharmacodynamic biomarker to see if a drug is successfully hitting its target. A lower Poly(GP) level does not necessarily mean clinical progression has improved [9][15].

Future Directions: Research and Clinical Trials

(Note: Clinical trial status reflects the landscape as of 2026. Research participation does not guarantee access, benefit, or future treatment.)

The landscape for C9ORF72 research is moving toward precision medicine, trying to “silence” the expanded gene [16].

  • Gene Silencing: Technologies like Antisense Oligonucleotides (ASOs) act on RNA transcripts [17]. Other approaches, like CRISPR/Cas9, edit DNA but have largely been in preclinical (laboratory) stages [18].
  • Learning from Failures: Early trials of some ASOs (like BIIB078) were stopped because they didn’t show clinical benefit, even though they successfully lowered Poly(GP) levels [17]. This important negative result taught researchers that target engagement alone is not enough [19][20].
  • Prevention Trials: Some research is focused on pre-symptomatic carriers [21]. The goal is to identify treatment windows, though supportive care remains the current foundation [20][22].

By staying connected to a specialized center, you and your family can stay informed about trial registries and potential observational studies [23].

Common questions in this guide

How often should C9ORF72 Huntington disease-like syndrome be monitored?
There is no single schedule that fits everyone. Follow-up is usually individualized and may include movement, cognitive or behavioral, and respiratory assessments at intervals based on symptoms, test results, and the recommendations of your care team.
What is the difference between FVC and SNIP in C9ORF72 monitoring?
FVC estimates how much air you can forcefully exhale, while SNIP estimates inspiratory pressure and provides information about diaphragm strength. Clinicians may also use lying-down FVC, cough-strength testing, and overnight breathing tests; results should be interpreted together because some tests depend on effort.
What does a high or rising NfL level mean?
NfL is a protein released when nerve cells are damaged, but it is not specific to C9ORF72 disease and can be affected by age and other factors. A single or rising result cannot by itself diagnose symptom onset, predict your exact disease pattern, or determine treatment.
Does a lower Poly(GP) level mean that my disease is improving?
Not necessarily. Poly(GP) is used in clinical trials to show whether a treatment is affecting its intended biological target, but a lower level does not prove that symptoms or clinical progression have improved.
Are gene-silencing treatments available for C9ORF72 syndrome?
Antisense oligonucleotides are being studied, while CRISPR/Cas9 approaches have largely remained in preclinical research. An earlier antisense trial lowered Poly(GP) without producing clinical benefit, so trial eligibility and potential benefit must be discussed with a specialized center.
Which symptoms should prompt a breathing or swallowing assessment?
Tell your care team about new or worsening swallowing difficulty, slurred speech, weight loss, waking with headaches, unusual daytime tiredness, or needing more pillows to sleep comfortably. These changes may lead to breathing tests, a swallowing evaluation, or other supportive care.

Get notified when new evidence is published on Huntington disease-like syndrome due to C9ORF72 expansions.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (23)
  1. 1

    Cumulative incidence of motor and cognitive features in the amyotrophic lateral sclerosis-frontotemporal degeneration spectrum.

    Spencer BE, Xie SX, Ohm DT, et al.

    Brain communications 2025; (7(6)):fcaf405 doi:10.1093/braincomms/fcaf405.

    PMID: 41216140
  2. 2

    Motor, cognitive and behavioural profiles of C9orf72 expansion-related amyotrophic lateral sclerosis.

    Colombo E, Poletti B, Maranzano A, et al.

    Journal of neurology 2023; (270(2)):898-908 doi:10.1007/s00415-022-11433-z.

    PMID: 36308529
  3. 3

    The C9orf72 expansion is associated with accelerated respiratory function decline in a large Amyotrophic Lateral Sclerosis cohort.

    Rooney J, Murray D, Campion A, et al.

    HRB open research 2019; (2()):23 doi:10.12688/hrbopenres.12940.1.

    PMID: 32296747
  4. 4

    Initiating non-invasive ventilation in patients with Amyotrophic Lateral Sclerosis in The Netherlands: A centralised approach to respiratory care.

    Jaspers Focks RJ, Helleman J, van den Berg LH, et al.

    Journal of neuromuscular diseases 2025; (12(3)):372-381 doi:10.1177/22143602251319167.

    PMID: 40091372
  5. 5

    Phenotypical Characterization of C9ALS Patients from the Emilia Romagna Registry of ALS: A Retrospective Case-Control Study.

    Ghezzi A, Gianferrari G, Baldassarri E, et al.

    Genes 2025; (16(3)) doi:10.3390/genes16030309.

    PMID: 40149460
  6. 6

    Respiratory Failure in Amyotrophic Lateral Sclerosis.

    Niedermeyer S, Murn M, Choi PJ

    Chest 2019; (155(2)):401-408 doi:10.1016/j.chest.2018.06.035.

    PMID: 29990478
  7. 7

    Practical recommendations for the treatment of chorea associated with Huntington's disease: An expert consensus.

    Furr Stimming E, Bang J, Brown A, et al.

    Journal of Huntington's disease 2026; 18796397261468482 doi:10.1177/18796397261468482.

    PMID: 42446188
  8. 8

    Cognitive and behavioral manifestations of the C9orf72 mutation in Amyotrophic Lateral Sclerosis: an age, education, and gender-matched cohort study.

    O'Farrell S, Holland MC, Peelo C, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2026; 1-8 doi:10.1080/21678421.2026.2721333.

    PMID: 42661580
  9. 9

    Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers.

    Meeter LHH, Gendron TF, Sias AC, et al.

    Annals of clinical and translational neurology 2018; (5(5)):583-597 doi:10.1002/acn3.559.

    PMID: 29761121
  10. 10

    Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis.

    Gendron TF, Chew J, Stankowski JN, et al.

    Science translational medicine 2017; (9(383)) doi:10.1126/scitranslmed.aai7866.

    PMID: 28356511
  11. 11

    Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases.

    Palermo G, Mazzucchi S, Della Vecchia A, et al.

    Molecular neurobiology 2020; (57(11)):4667-4691 doi:10.1007/s12035-020-02035-9.

    PMID: 32772223
  12. 12

    Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications.

    Saracino D, Dorgham K, Camuzat A, et al.

    Journal of neurology, neurosurgery, and psychiatry 2021; (92(12)):1278-1288 doi:10.1136/jnnp-2021-326914.

    PMID: 34349004
  13. 13

    Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study.

    van der Ende EL, Meeter LH, Poos JM, et al.

    The Lancet. Neurology 2019; (18(12)):1103-1111 doi:10.1016/S1474-4422(19)30354-0.

    PMID: 31701893
  14. 14

    Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis.

    Wilson KM, Katona E, Glaria I, et al.

    Journal of neurology, neurosurgery, and psychiatry 2022; (93(7)):761-771 doi:10.1136/jnnp-2021-328710.

    PMID: 35379698
  15. 15

    Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial.

    Babu S, Nicholson KA, Rothstein JD, et al.

    Brain : a journal of neurology 2024; (147(9)):2998-3008 doi:10.1093/brain/awae109.

    PMID: 38606777
  16. 16

    Preclinical evaluation of WVE-004, aninvestigational stereopure oligonucleotide forthe treatment of C9orf72-associated ALS or FTD.

    Liu Y, Andreucci A, Iwamoto N, et al.

    Molecular therapy. Nucleic acids 2022; (28()):558-570 doi:10.1016/j.omtn.2022.04.007.

    PMID: 35592494
  17. 17

    Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS.

    McEachin ZT, Chung M, Stratton SA, et al.

    Cell 2025; (188(23)):6424-6435.e17 doi:10.1016/j.cell.2025.07.045.

    PMID: 40865525
  18. 18

    CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro.

    Meijboom KE, Abdallah A, Fordham NP, et al.

    Nature communications 2022; (13(1)):6286 doi:10.1038/s41467-022-33332-7.

    PMID: 36271076
  19. 19

    G2C4 targeting antisense oligonucleotides potently mitigate TDP-43 dysfunction in human C9orf72 ALS/FTD induced pluripotent stem cell derived neurons.

    Rothstein JD, Baskerville V, Rapuri S, et al.

    Acta neuropathologica 2023; (147(1)):1 doi:10.1007/s00401-023-02652-3.

    PMID: 38019311
  20. 20

    Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit.

    Sattler R, Traynor BJ, Robertson J, et al.

    Neurology and therapy 2023; (12(6)):1821-1843 doi:10.1007/s40120-023-00548-8.

    PMID: 37847372
  21. 21

    Plasma microRNA signature in presymptomatic and symptomatic subjects with C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis.

    Kmetzsch V, Anquetil V, Saracino D, et al.

    Journal of neurology, neurosurgery, and psychiatry 2021; (92(5)):485-493 doi:10.1136/jnnp-2020-324647.

    PMID: 33239440
  22. 22

    How can we define the presymptomatic C9orf72 disease in 2022? An overview on the current definitions of preclinical and prodromal phases.

    Saracino D, Le Ber I

    Revue neurologique 2022; (178(5)):426-436 doi:10.1016/j.neurol.2022.03.007.

    PMID: 35525633
  23. 23

    The optimisation of noninvasive ventilation in amyotrophic lateral sclerosis: a systematic review.

    O'Brien D, Stavroulakis T, Baxter S, et al.

    The European respiratory journal 2019; (54(3)) doi:10.1183/13993003.00261-2019.

    PMID: 31273038

This page is for informational purposes only and does not constitute medical advice. Your neurology and respiratory care team should interpret monitoring results and discuss whether a clinical trial or research study is appropriate for you.

Guide contents Huntington disease-like syndrome due to C9ORF72 expansions
Research & Literature
05 Genetic Counseling and Family Implications